PURPOSE: To develop a nanostructured lipid carrier (NLC) co-loaded with doxorubicin and docosahexaenoic acid (DHA) and to evaluate its potential to overcome drug resistance and to increase antitumoral effect in MCF-7/Adr cancer cell line. METHODS: The NLC was prepared by a hot homogenization method and characterized for size, zeta potential, entrapment efficiency (EE) and drug loading (DL). Drug release was evaluated by dialysis in complete DMEM, and NLC aggregation was assayed in the presence of serum. The cytotoxicity of formulations, doxorubicin uptake or penetration were evaluated in MCF-7 and MCF-7/Adr as monolayer or spheroid models. RESULTS: The formulation had a size of about 80 nm, negative zeta potential, EE of 99%, DL of 31 mg/g, a controlled drug release in DMEM and no particles aggregation in presence of serum. The NLC loaded with doxorubicin and DHA showed the same activity as free drugs against MCF-7 but a stronger activity against MCF-7/Adr cells. In monolayer model, the doxorubicin uptake as free and encapsulated form was similar in MCF-7 but higher for the encapsulated drug in MCF-7/Adr, suggesting a bypassing of P-glycoprotein bomb efflux. For spheroids, the NLC loaded with doxorubicin and DHA showed a prominent cytotoxicity and a greater penetration of doxorubicin. CONCLUSIONS: These findings suggest that the co-encapsulation of doxorubicin and DHA in NLC enhances the cytotoxicity and overcomes the doxorubicin resistance in MCF-7/Adr.
PURPOSE: To develop a nanostructured lipid carrier (NLC) co-loaded with doxorubicin and docosahexaenoic acid (DHA) and to evaluate its potential to overcome drug resistance and to increase antitumoral effect in MCF-7/Adr cancer cell line. METHODS: The NLC was prepared by a hot homogenization method and characterized for size, zeta potential, entrapment efficiency (EE) and drug loading (DL). Drug release was evaluated by dialysis in complete DMEM, and NLC aggregation was assayed in the presence of serum. The cytotoxicity of formulations, doxorubicin uptake or penetration were evaluated in MCF-7 and MCF-7/Adr as monolayer or spheroid models. RESULTS: The formulation had a size of about 80 nm, negative zeta potential, EE of 99%, DL of 31 mg/g, a controlled drug release in DMEM and no particles aggregation in presence of serum. The NLC loaded with doxorubicin and DHA showed the same activity as free drugs against MCF-7 but a stronger activity against MCF-7/Adr cells. In monolayer model, the doxorubicin uptake as free and encapsulated form was similar in MCF-7 but higher for the encapsulated drug in MCF-7/Adr, suggesting a bypassing of P-glycoprotein bomb efflux. For spheroids, the NLC loaded with doxorubicin and DHA showed a prominent cytotoxicity and a greater penetration of doxorubicin. CONCLUSIONS: These findings suggest that the co-encapsulation of doxorubicin and DHA in NLC enhances the cytotoxicity and overcomes the doxorubicin resistance in MCF-7/Adr.
Authors: J Jassem; T Pieńkowski; A Płuzańska; S Jelic; V Gorbunova; Z Mrsic-Krmpotic; J Berzins; T Nagykalnai; N Wigler; J Renard; S Munier; C Weil Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Renata S Fernandes; Juliana O Silva; Samuel V Mussi; Sávia C A Lopes; Elaine A Leite; Geovanni D Cassali; Valbert N Cardoso; Danyelle M Townsend; Patrick M Colletti; Lucas A M Ferreira; Domenico Rubello; André L B de Barros Journal: Mol Imaging Biol Date: 2018-06 Impact factor: 3.488
Authors: Samuel V Mussi; Gaurav Parekh; Pravin Pattekari; Tatyana Levchenko; Yuri Lvov; Lucas A M Ferreira; Vladimir P Torchilin Journal: Int J Pharm Date: 2015-09-07 Impact factor: 5.875
Authors: Marie Millard; Ilya Yakavets; Vladimir Zorin; Aigul Kulmukhamedova; Sophie Marchal; Lina Bezdetnaya Journal: Int J Nanomedicine Date: 2017-10-31
Authors: Khaled M Hosny; Amal M Sindi; Sarah Ali; Waleed S Alharbi; Maher S Hajjaj; Haitham A Bukhary; Moutaz Y Badr; Rayan Y Mushtaq; Samar S A Murshid; Alshaimaa M Almehmady; Rana B Bakhaidar; Eman Alfayez; Mallesh Kurakula Journal: Drug Deliv Date: 2022-12 Impact factor: 6.419